<DOC>
	<DOC>NCT02268032</DOC>
	<brief_summary>Evaluate the effect of continuous administration of DHEA or other androgenic agents on ovarian reserve markers in women with diminished ovarian reserve (ROD), such as antral follicle count and AMH concentrations.</brief_summary>
	<brief_title>Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve</brief_title>
	<detailed_description>Healthy women protected from pregnancy by surgical sterilization, with no contraindications to use androgen therapy, attending the clinic of IDIMI were are invited to participate. Project Objetives : The general objective is evaluate pharmacokinetic parameters of three vaginal rings local and extended release, containing dehydroepiandrosterone (DHEA), testosterone or association of both hormones, compared with oral administration of DHEA and testosterone transdermal in women Secondary objectives are to assess its effects on the hormonal profile, tolerability and incidence of adverse events. - DHEA and/or, testosterone levels - Estradiol, FSH, SHBG, androstenediona, cortisol matinal, IGF1.levels - Tolerability and safety assessment by the use of the vaginal ring. - The incidence of adverse events</detailed_description>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1. Women between 38 and 45 years of age who have not used hormonal contraceptive methods at least for the past two months, or who have been surgically sterilized, with no contraindications for androgenic therapy. 2. Women with preserved menstrual cycles. 3. Women smoking less than 5 cigarettes daily. 4. AMH between 0.51.1 ng/mL 5. Total AFC 57 1. Women receiving medications that interact with DHEA metabolism (Anastrozole, exemestane, Fulvestrant, Insulin, Letrozole, Tamoxifen, Triazolam). 2. Women with diabetes mellitus 3. Women with untreated or decompensated endocrine disorders 4. Women with a prior history of ovarian surgery or oophorectomy</criteria>
	<gender>Female</gender>
	<minimum_age>38 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>hormone replacement therapy</keyword>
</DOC>